| Fulvestrant studied in …STUDIED_INderived200 of 384show all (up to 200) |
|---|
| → studied in | NCT05038735Phase 3 · active not recruiting Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05564377Phase 2 · recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · 384 trials list this drug (139 active) | — | — | Malignant Solid Neoplasm,Primary Peritoneal Carcinoma,Malignant Female Reproductive System Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05646862Phase 3 · recruiting A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05867251Phase 1/Phase 2 · recruiting Study of AVZO-021 in Patients With Advanced Solid Tumors · 384 trials list this drug (139 active) | — | — | Solid Neoplasm,Malignant Fallopian Tube Neoplasm,Ovarian Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06110793Phase 1/Phase 2 · active not recruiting A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06120283Phase 1 · recruiting BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors · 384 trials list this drug (139 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm,Hormone Receptor-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07226349Phase 1 · recruiting A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors · 384 trials list this drug (139 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03643510Phase 2 · completed Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer · 384 trials list this drug (139 active) | — | — | Endometrial Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06979596Phase 2 · recruiting A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) · 384 trials list this drug (139 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02860000Phase 2 · completed Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm,Invasive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04224272Phase 2 · completed Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant · 384 trials list this drug (139 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05384119Phase 1 · terminated Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06179303Phase 2 · recruiting Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer · 384 trials list this drug (139 active) | — | — | HER2-Negative Breast Carcinoma,Hormone Receptor-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07174336Phase 3 · recruiting A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) · 384 trials list this drug (139 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04524000Phase 2 · active not recruiting Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04544189Phase 2 · active not recruiting Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer · 384 trials list this drug (139 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05161195Phase 4 · active not recruiting Roll-over Study to Allow Continued Access to Ribociclib · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07679269Phase 2 · not yet recruiting Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety. · 384 trials list this drug (139 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07109726Phase 1/Phase 2 · recruiting A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations · 384 trials list this drug (139 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm,Esophageal Squamous Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07748208Phase 2 · not yet recruiting A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00099437Phase 3 · active not recruiting Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03531645Phase 2 · active not recruiting Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06065748Phase 3 · active not recruiting A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06756932Phase 1 · recruiting BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03147287Phase 2 · active not recruiting Palbociclib After CDK and Endocrine Therapy (PACE) · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04191499Phase 2/Phase 3 · active not recruiting A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05870579Phase 1 · active not recruiting [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03424005Phase 1/Phase 2 · recruiting A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07811232Phase 1/Phase 2 · not yet recruiting A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers · 384 trials list this drug (139 active) | — | — | Breast Neoplasm,Soft Tissue Sarcoma,Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05226871Phase 2 · active not recruiting Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm,Malignant Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06625775Phase 1 · recruiting Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors · 384 trials list this drug (139 active) | — | — | Adult Solid Neoplasm,Malignant Breast Neoplasm,Malignant Lung Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03006172Phase 1 · active not recruiting To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer · 384 trials list this drug (139 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03939897Phase 1 · active not recruiting Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | Breast Neoplasm,Breast Carcinoma,HER2-Negative Breast Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05307705Phase 1 · recruiting A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07347600recruiting A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07405801Phase 2 · recruiting A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07287917Phase 1/Phase 2 · recruiting Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors · 384 trials list this drug (139 active) | — | — | Breast Neoplasm,Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07368998Phase 2 · recruiting To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07604571Phase 1 · recruiting Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06982521Phase 3 · recruiting Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06380751Phase 3 · recruiting Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02955394Phase 2 · active not recruiting Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06428396Phase 2 · active not recruiting Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07029399Phase 1 · recruiting A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors · 384 trials list this drug (139 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06726148Phase 1/Phase 2 · recruiting Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors · 384 trials list this drug (139 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02536742Phase 2 · completed Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04214288Phase 2 · active not recruiting A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07787520Phase 1 · not yet recruiting A Study of LAE118 as Monotherapy and in Combination With Antitumor Agents in Advanced Solid Tumors · 384 trials list this drug (139 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04579380Phase 2 · active not recruiting Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations · 384 trials list this drug (139 active) | — | — | Urinary Tract Neoplasm,Lung Non-Small Cell Carcinoma,Uterine Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06105632Phase 2 · active not recruiting A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment · 384 trials list this drug (139 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03959891Phase 1 · active not recruiting AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC) · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07408089Phase 1 · terminated Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06047184Phase 1 · completed Phase I Study of BEBT-209 in Women With Advanced Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04862663Phase 3 · active not recruiting Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06635447Phase 3 · active not recruiting Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06016738Phase 3 · active not recruiting OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer · 384 trials list this drug (139 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05090358Phase 2 · active not recruiting Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06680921Phase 3 · active not recruiting A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE) · 384 trials list this drug (139 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06998407Phase 1/Phase 2 · recruiting ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02206984Phase 2 · completed Endocrine Response in Women With Invasive Lobular Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04556773Phase 1 · active not recruiting A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05154487Phase 2 · active not recruiting A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07288359Phase 1/Phase 2 · recruiting Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors · 384 trials list this drug (139 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07426822Phase 2 · recruiting Rash & Diarrhea Prophylaxis With Capivasertib · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02476786Phase 2 · recruiting Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score · 384 trials list this drug (139 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04053322Phase 2 · active not recruiting Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04975308Phase 3 · active not recruiting A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer · 384 trials list this drug (139 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07318805Phase 1 · recruiting A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm,Colorectal Adenocarcinoma,Malignant Colorectal Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05238922Phase 1 · active not recruiting Study of INCB123667 in Subjects With Advanced Solid Tumors · 384 trials list this drug (139 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07716046Phase 2 · not yet recruiting Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04572295Phase 1 · completed A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04115306Phase 1/Phase 2 · active not recruiting Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05467891Phase 2 · recruiting Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07117630Phase 2 · recruiting An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03439046Phase 3 · terminated Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06997029Phase 1 · recruiting A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors · 384 trials list this drug (139 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07096024completed A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market · 384 trials list this drug (139 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05631795Phase 4 · completed Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04567420Phase 2 · active not recruiting DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE) · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05768139Phase 1/Phase 2 · recruiting First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors · 384 trials list this drug (139 active) | — | — | Adult Solid Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06239467Phase 1 · active not recruiting First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Neoplasm,Solid Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06764186Phase 3 · active not recruiting A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain · 384 trials list this drug (139 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07558733Phase 1/Phase 2 · recruiting Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03179904Phase 2 · completed TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | Breast Carcinoma,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07666555Phase 2 · recruiting A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy. · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02792465Phase 1 · completed A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm,Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03363893Phase 1/Phase 2 · completed Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05573126Phase 1/Phase 2 · recruiting Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07570966Phase 1/Phase 2 · withdrawn Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors · 384 trials list this drug (139 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06257264Phase 1 · active not recruiting A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors · 384 trials list this drug (139 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm,Malignant Gastric Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05306340Phase 3 · active not recruiting A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) · 384 trials list this drug (139 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07540572Phase 1 · recruiting A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors · 384 trials list this drug (139 active) | — | — | Lung Non-Small Cell Carcinoma,Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06494150Phase 2 · active not recruiting Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO) · 384 trials list this drug (139 active) | — | — | Ovarian Low Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06253195Phase 1 · completed BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors · 384 trials list this drug (139 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01953588Phase 3 · active not recruiting Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm,Invasive Breast Carcinoma of No Special Type,Invasive Breast Lobular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02738866Phase 2 · active not recruiting Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07619066Phase 2 · not yet recruiting A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations. · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00585507Phase 2 · active not recruiting Efficacy and Safety of 500mg of Fulvestrant · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05392608Phase 2 · active not recruiting SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast) · 384 trials list this drug (139 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03425838Phase 3 · active not recruiting Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05319873Phase 1/Phase 2 · active not recruiting Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer · 384 trials list this drug (139 active) | — | — | Invasive Breast Carcinoma,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05601440Phase 2 · recruiting Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07062965Phase 3 · recruiting A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04305496Phase 3 · active not recruiting Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05608252Phase 1/Phase 2 · recruiting VS-6766+Abema+Fulv in Met HR+/HER- BC · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03633331Phase 2 · completed Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05683418Phase 1 · recruiting A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04606446Phase 2 · recruiting Study of PF-07248144 in Advanced or Metastatic Solid Tumors · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04920708Phase 2 · active not recruiting Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression · 384 trials list this drug (139 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04650581Phase 3 · active not recruiting Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04796623Phase 2 · completed A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07389733Phase 1/Phase 2 · recruiting A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05735080Phase 1/Phase 2 · recruiting Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer · 384 trials list this drug (139 active) | — | — | Malignant Neoplasm,Solid Neoplasm,Malignant Breast Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06954961Phase 3 · recruiting A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05654623Phase 3 · active not recruiting A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07480681Phase 1 · not yet recruiting Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05230810Phase 1/Phase 2 · active not recruiting Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06736704Phase 1/Phase 2 · recruiting SNV4818 in Participants With Advanced Solid Tumors · 384 trials list this drug (139 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05524584Phase 2 · recruiting Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01560416Phase 2 · completed Fulvestrant With or Without Ganetespib in HR+ Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05554354Phase 2 · terminated Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial) · 384 trials list this drug (139 active) | — | — | HER2-Negative Breast Carcinoma,Hormone Receptor-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01602380Phase 3 · completed A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01597388Phase 1 · completed AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02778685Phase 2 · active not recruiting Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer · 384 trials list this drug (139 active) | — | — | Breast Neoplasm,Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04059484Phase 2 · terminated Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02947685Phase 3 · active not recruiting Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05101564Phase 2 · completed Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05501886Phase 3 · active not recruiting Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02763566Phase 3 · active not recruiting A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03781063Phase 2 · completed Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation · 384 trials list this drug (139 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02057133Phase 1 · active not recruiting A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread · 384 trials list this drug (139 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07024173Phase 3 · recruiting A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03289039Phase 2 · terminated Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05933395Phase 2 · recruiting Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05169567Phase 3 · active not recruiting Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer · 384 trials list this drug (139 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03056755Phase 2 · completed Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03685331Phase 1 · completed HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05082025Phase 2 · terminated Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations · 384 trials list this drug (139 active) | — | — | Malignant Ovarian Neoplasm,Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06663072Phase 1 · recruiting Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors · 384 trials list this drug (139 active) | — | — | Pancreatic Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07330544Phase 2 · recruiting A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05365178Phase 3 · active not recruiting To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06408168Phase 2 · terminated Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial) · 384 trials list this drug (139 active) | — | — | Invasive Breast Lobular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03393845Phase 2 · active not recruiting Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04762979Phase 2 · active not recruiting Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | Hormone Receptor-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07207070Phase 3 · recruiting A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer. · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05963984Phase 2 · completed A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02760030Phase 2 · completed Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04603183Phase 2 · completed ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06409390Phase 2 · recruiting Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05252416Phase 1 · terminated (VELA) Study of BLU-222 in Advanced Solid Tumors · 384 trials list this drug (139 active) | — | — | Solid Neoplasm,Carcinosarcoma,Malignant Gastric Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01992952Phase 1/Phase 2 · active not recruiting Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07235618Phase 2 · not yet recruiting A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07180160Phase 2 · recruiting Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03280563Phase 1/Phase 2 · completed A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer · 384 trials list this drug (139 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02107703Phase 3 · active not recruiting A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer · 384 trials list this drug (139 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06784193Phase 1 · recruiting Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05216432Phase 1 · recruiting First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer · 384 trials list this drug (139 active) | — | — | Breast Neoplasm,Solid Neoplasm,Adult Solid Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02958852Phase 2 · completed A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05063786Phase 3 · active not recruiting Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05113368Phase 2 · recruiting Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer · 384 trials list this drug (139 active) | — | — | Malignant Ovarian Neoplasm,Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04300790Phase 2 · completed Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05181033Phase 2 · recruiting Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06208410Phase 1/Phase 2 · recruiting A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors · 384 trials list this drug (139 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04352777Phase 2 · completed Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer · 384 trials list this drug (139 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03767335Phase 1 · completed MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03099174Phase 1 · completed This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer · 384 trials list this drug (139 active) | — | — | Neoplasm,Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06515470Phase 1 · recruiting Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00253422Phase 3 · completed Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03294694Phase 1 · terminated Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer · 384 trials list this drug (139 active) | — | — | Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06998108Phase 3 · recruiting Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy · 384 trials list this drug (139 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01441947Phase 2 · completed Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05054374Phase 1/Phase 2 · completed A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer · 384 trials list this drug (139 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,Solid Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03554044Phase 1 · completed T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer · 384 trials list this drug (139 active) | — | — | Breast Carcinoma,Invasive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05251714Phase 1/Phase 2 · active not recruiting CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer · 384 trials list this drug (139 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05759949Phase 1 · completed First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors · 384 trials list this drug (139 active) | — | — | Solid Neoplasm,Adult Solid Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06957379Phase 2 · active not recruiting Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy · 384 trials list this drug (139 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06941142Phase 1 · not yet recruiting A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05536128Phase 2 · recruiting Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06929325Phase 3 · not yet recruiting Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors · 384 trials list this drug (139 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06607757Phase 2 · recruiting Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06856200NA · recruiting A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03169764Phase 1/Phase 2 · withdrawn QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy · 384 trials list this drug (139 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03169738Phase 1/Phase 2 · withdrawn QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors · 384 trials list this drug (139 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03169777Phase 1/Phase 2 · withdrawn QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC · 384 trials list this drug (139 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03197571Phase 1/Phase 2 · withdrawn QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy · 384 trials list this drug (139 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03197584Phase 1/Phase 2 · withdrawn QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy · 384 trials list this drug (139 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03691493Phase 2 · completed Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis · 384 trials list this drug (139 active) | — | — | Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02437318Phase 3 · completed Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03854903Phase 1 · completed WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04256941Phase 2 · terminated Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study · 384 trials list this drug (139 active) | — | — | Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05176080Phase 1/Phase 2 · terminated Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02491983Phase 2 · completed Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02632045Phase 2 · completed Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm,Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04985266Phase 2 · recruiting A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02216786Phase 2 · completed A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02675231Phase 2 · completed A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03238196Phase 1 · completed Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04060862Phase 1 · terminated A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04899349Phase 2 · terminated Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02028507Phase 3 · completed Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors · 384 trials list this drug (139 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |